CSL Behring
WEBCSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas.
Global Biotechnology Company | CSL
WEBCSL Behring is a global biotech leader with a broad range of biotherapies for rare and serious diseases including bleeding disorders, immunodeficiencies, hereditary angioedema, neurological disorders and Alpha 1 Antitrypsin Deficiency.
CSL Behring - Wikipedia
WEBCSL Behring is a biopharmaceutical company, manufacturing plasma-derived and recombinant therapeutic products. [2] The company is a combination of Behringwerke, founded in 1904 in Marburg , Germany by Emil von Behring , and the Commonwealth Serum Laboratories (CSL), established in Australia in 1916 to provide vaccines to the people of Australia ...
CSL Behring Products
WEBCSL Behring is a global leader in developing and delivering high-quality medicines that treat people with rare and serious diseases.
Our Company - CSL Behring
WEBIn the century since, CSL Behring has grown into a global biotechnology leader, driven by that same promise to save and improve lives. We offer the broadest range of quality plasma-derived and recombinant therapies in our industry.
CSL Behring Announces the First Patient Has Received FDA …
WEBJun 20, 2023 · A total of 54 patients received a single dose of HEMGENIX ® in the pivotal trial, with 53 patients completing at least 18 months of follow-up. The primary endpoint in the pivotal HOPE-B study was ABR 52 weeks after achievement of stable factor IX expression (months 7 to 18) compared with the six-month lead-in period.
Our Company - CSL Behring
WEBCSL Behring's portfolio of innovative medicines includes a wide range of recombinant and plasma-derived products for treating bleeding disorders, immune deficiencies and chronic inflammatory demyelinating polyneuropathy, as well as hereditary angioedema and Alpha 1 Antitrypsin Deficiency.
Global Newsroom | CSL
WEBBiotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry. CSL Behring: Rare & Serious Diseases Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine companies.
CSL Behring Canada
WEBWelcome to CSL Behring Canada. Our portfolio of innovative medicines includes a wide range of recombinant and plasma-derived products for treating bleeding disorders, immune deficiencies, and chronic inflammatory demyelinating polyneuropathy, as well as hereditary angioedema and Alpha-1 Antitrypsin Deficiency.
U.S. Food and Drug Administration approves CSL's HEMGENIX ...
WEBNov 22, 2022 · Global biotechnology leader CSL (ASX: CSL) today announced that the U.S. Food and Drug Administration (FDA) approved HEMGENIX® (etranacogene dezaparvovec-drlb), the first and only one-time gene therapy for appropriate adults with hemophilia B.
Skip to content